.svg)
You've been taking a supplement for weeks because someone said it helped their mood, but you feel no different. Or maybe you've read conflicting advice from wellness influencers, doctors, and supplement brands about what actually works for depression. The gap between marketing claims and clinical evidence is wide, and knowing which supplements have real research behind them matters when you're trying to support your mental health.
Superpower insight: Members who track their vitamin D, B12, folate, and thyroid markers are better positioned to identify nutritional gaps that contribute to low mood, making supplement decisions more targeted than trial and error.
What Supplements Actually Do in the Brain
When people ask what supplements help with depression, they're usually asking about compounds that affect neurotransmitter production, inflammation, or cellular energy metabolism. Depression isn't simply a serotonin deficiency, but several supplements influence the biochemical pathways involved in mood regulation.
Omega-3 fatty acids and brain cell membranes
Omega-3 fatty acids, particularly EPA and DHA, are structural components of neuronal cell membranes. A 2010 meta-analysis found that EPA appears to reduce inflammatory signaling in the brain, while DHA supports membrane fluidity and receptor function. Low omega-3 levels correlate with higher rates of depression in epidemiological studies.
Vitamin D and neurotransmitter synthesis
Vitamin D receptors are found throughout the brain, including in regions involved in mood regulation. Vitamin D plays a role in the synthesis of serotonin and dopamine. A 2024 meta-analysis found that deficiency is associated with increased depressive symptoms, and supplementation may help restore normal neurotransmitter signaling in deficient individuals.
SAMe and methylation pathways
S-adenosylmethionine (SAMe) is a naturally occurring molecule that serves as a methyl donor in numerous biochemical reactions, including the synthesis of neurotransmitters such as serotonin, dopamine, and norepinephrine. A 2024 meta-analysis confirmed SAMe's role in supporting methylation-dependent neurotransmitter production.
Methylfolate and neurotransmitter production
L-methylfolate is the only form of folate that crosses the blood-brain barrier. It is a critical cofactor in the synthesis of serotonin, dopamine, and norepinephrine. People with MTHFR gene variants have reduced ability to convert folic acid into its active form, potentially impairing neurotransmitter production. Randomized controlled trials have shown that supplementation with L-methylfolate at 15 mg/day can improve outcomes in SSRI-resistant depression.
How These Supplements Affect Mood and Brain Function
Omega-3s reduce neuroinflammation
EPA reduces levels of pro-inflammatory cytokines in the brain, including IL-1beta, IL-6, and TNF-alpha. Chronic neuroinflammation is increasingly recognized as a contributor to depressive symptoms. A 2019 meta-analysis in Translational Psychiatry found that EPA-enriched formulations (at least 60% EPA of total EPA+DHA) significantly reduced depression severity, which may explain why EPA-rich formulations outperform DHA-only supplements in depression trials.
Vitamin D modulates the HPA axis
Vitamin D receptors are present in the hypothalamus and other brain regions that regulate the hypothalamic-pituitary-adrenal (HPA) axis. Vitamin D may help modulate cortisol and stress responses, which are frequently dysregulated in depression. However, the evidence for direct HPA axis modulation by vitamin D supplementation in depressed individuals remains preliminary.
SAMe increases neurotransmitter availability
SAMe donates methyl groups required for the enzymatic conversion of precursors into serotonin, dopamine, and norepinephrine. It also contributes to the synthesis of phosphatidylcholine, a component of neuronal cell membranes. A review of the evidence found that SAMe may increase monoamine turnover and enhance neurotransmitter receptor sensitivity.
Methylfolate supports monoamine synthesis
L-methylfolate is an essential cofactor for the enzyme that converts tryptophan into serotonin and tyrosine into dopamine and norepinephrine. When folate metabolism is impaired, as in people with MTHFR C677T variants, monoamine synthesis may be reduced. Papakostas et al. (2012) demonstrated that adjunctive L-methylfolate at 15 mg/day significantly improved depression outcomes in SSRI-resistant patients.
What Clinical Research Shows About Efficacy
Omega-3 fatty acids
A 2019 meta-analysis of 26 RCTs found that omega-3 supplementation significantly reduced depressive symptoms compared to placebo (SMD = -0.28). EPA doses of 1 to 2 grams per day appear most effective, particularly when EPA comprises at least 60% of total EPA+DHA and when used as adjunctive therapy alongside antidepressants. DHA-only formulations show weaker effects. The benefit is most pronounced in people with higher baseline inflammation.
Vitamin D
A 2024 dose-response meta-analysis of 31 RCTs with 24,189 participants found that vitamin D3 supplementation modestly reduced depressive symptoms (SMD: -0.32), with stronger effects in individuals with existing depressive symptoms (SMD: -0.57). The benefit was observed with doses of 2,000 IU daily and above. Trials lasting 8 to 24 weeks showed the strongest effects, while trials shorter than eight weeks showed minimal benefit. The evidence is strongest for people with vitamin D deficiency (below 20 ng/mL).
SAMe
A 2024 meta-analysis of 23 trials with 2,183 participants found that SAMe was superior to placebo (SMD: -0.58) and comparable to tricyclic antidepressants for treating depression. Doses of 800 to 1,600 mg per day (divided into two doses) are most commonly studied. An RCT testing 800 mg/day found a clinically relevant effect size (d = 0.72) favoring SAMe over placebo as monotherapy, though the result did not reach statistical significance in the small sample. SAMe has also shown benefit as an adjunct to SSRIs in nonresponders, though evidence for adjunctive use is mixed across studies. Some studies suggest onset of effect within 1 to 2 weeks, but this has not been rigorously confirmed in head-to-head comparisons with standard antidepressants.
Methylfolate
Two randomized, double-blind trials by Papakostas et al. found that adjunctive L-methylfolate at 15 mg/day significantly improved depression outcomes in SSRI-resistant patients, while the 7.5 mg/day dose did not show significant benefit. The effect is most pronounced when combined with SSRIs or SNRIs. Biomarkers such as elevated hs-CRP (above 3 mg/L) and high BMI may be stronger predictors of L-methylfolate response than MTHFR genotype alone. L-methylfolate alone has not been extensively studied as monotherapy for depression.
Dosing, Timing, and Formulation
Omega-3 fatty acids
Look for supplements with at least 1,000 mg of EPA per serving. The EPA-to-DHA ratio matters: meta-analyses suggest formulations where EPA comprises at least 60% of total EPA+DHA show better results in depression trials than balanced or DHA-dominant products. Triglyceride forms may absorb better than ethyl ester forms, particularly when not taken with a high-fat meal. Take with a fat-containing meal to improve absorption. Effects typically appear after 4 to 8 weeks of consistent use.
Vitamin D
Doses of 2,000 to 4,000 IU daily are standard for correcting deficiency. Vitamin D3 (cholecalciferol) is more effective than D2 (ergocalciferol) at raising blood levels. Take with a meal containing fat, as vitamin D is fat-soluble. Testing baseline levels before supplementing is essential, since excess vitamin D can cause toxicity. Retest after 8 to 12 weeks to assess response.
SAMe
Start with 400 mg twice daily and increase to 800 mg twice daily if tolerated. SAMe is best absorbed on an empty stomach, 30 minutes before meals. Enteric-coated formulations reduce gastrointestinal side effects. SAMe degrades quickly, so store it in a cool, dry place and check expiration dates. Some studies suggest effects may appear within 1 to 2 weeks, though this has not been conclusively established in rigorous head-to-head comparisons with conventional antidepressants. Important: SAMe should not be used by individuals with bipolar disorder, as clinical studies have reported a significant risk of triggering mania or hypomania.
Methylfolate
The most effective dose in clinical trials is 15 mg daily; the 7.5 mg dose did not show significant benefit over placebo. L-methylfolate is typically used as an adjunct to antidepressants. Methylfolate is water-soluble and can be taken with or without food. It's often combined with vitamin B12 and B6, which support methylation pathways. Genetic testing for MTHFR variants can help identify who is most likely to benefit.
Who Responds and Who Doesn't
Baseline nutrient status
Supplements work best when they correct a deficiency. If your omega-3 index is already optimal or your vitamin D level is 40 ng/mL, adding more won't necessarily improve mood. Conversely, someone with a vitamin D level of 15 ng/mL may see significant improvement with supplementation. Testing baseline levels before starting is the most reliable way to predict response.
Genetic factors
MTHFR gene variants reduce the body's ability to convert folic acid into methylfolate, making supplementation with the active form more effective. Similarly, genetic differences in omega-3 metabolism and vitamin D receptor function influence how well you respond to these supplements. Pharmacogenomic testing can identify these variants.
Inflammation levels
People with elevated inflammatory markers like hs-CRP or IL-6 tend to respond better to omega-3 supplementation than those with low inflammation. Research suggests that depression with high inflammation may represent a distinct subtype that's more responsive to anti-inflammatory interventions.
Medication interactions
SAMe can interact with antidepressants, particularly MAO inhibitors and SSRIs, potentially increasing serotonin to unsafe levels (serotonin syndrome). A case report documented mania with psychotic features in a patient taking SAMe concurrently with an SSRI. SAMe should also be avoided in individuals with bipolar disorder due to the risk of triggering manic episodes. Omega-3s were historically thought to have blood-thinning effects, but a systematic review found no significant impact on bleeding risk at typical supplemental doses (up to 4 g/day), even when combined with anticoagulants. Nonetheless, patients on anticoagulant therapy should inform their prescriber before starting omega-3 supplementation. Vitamin D can interact with certain medications that affect calcium metabolism. Always disclose supplement use to your prescriber.
Severity of depression
Supplements show the most consistent benefit in mild to moderate depression. Severe depression typically requires more intensive intervention, and supplements are best used as adjuncts to medication or psychotherapy rather than standalone treatments.
Turning Research Into a Strategy That Works for You
Knowing your baseline biomarker levels before starting a supplement is more informative than guessing. If you're considering omega-3s, an omega-3 index test shows your current EPA and DHA levels. For vitamin D, a 25-hydroxyvitamin D test reveals whether you're deficient, sufficient, or optimal. Homocysteine and folate levels can indicate whether methylation pathways are functioning efficiently.
Tracking changes over time matters more than any single data point. Retest after 8 to 12 weeks of supplementation to see if levels have shifted and whether symptoms have improved. This approach removes guesswork and shows whether the intervention is working for your specific biology.
Relevant biomarkers to consider before supplementing for depression include:
- Omega-3 Index (EPA + DHA as a percentage of total red blood cell fatty acids)
- 25-Hydroxyvitamin D (sufficiency generally defined as above 30 ng/mL; the 2024 Endocrine Society guidelines note that an optimal target for disease prevention has not been established in clinical trials)
- Homocysteine (elevated levels suggest impaired methylation)
- Folate and B12 (low levels can impair neurotransmitter synthesis)
- hs-CRP (elevated inflammation may predict omega-3 response)
What Your Lab Results Can Tell You About Your Supplement Strategy
If you're taking supplements to support mood, Superpower's 100+ biomarker panel includes the markers that show whether your approach is working. Omega-3 levels, vitamin D status, homocysteine, folate, and inflammatory markers like hs-CRP reveal whether your current regimen is addressing the underlying biochemical imbalances that contribute to depression. You're not guessing based on how you feel; you're adjusting based on what your body is actually doing.
What Supplements Actually Do in the Brain
When people ask what supplements help with depression, they're usually asking about compounds that affect neurotransmitter production, inflammation, or cellular energy metabolism. Depression isn't simply a serotonin deficiency, but several supplements influence the biochemical pathways involved in mood regulation.
Omega-3 fatty acids and brain cell membranes
Omega-3 fatty acids, particularly EPA and DHA, are structural components of neuronal cell membranes. A 2010 meta-analysis found that EPA appears to reduce inflammatory signaling in the brain, while DHA supports membrane fluidity and receptor function. Low omega-3 levels correlate with higher rates of depression in epidemiological studies.
Vitamin D and neurotransmitter synthesis
Vitamin D receptors are found throughout the brain, including in regions involved in mood regulation. Vitamin D plays a role in the synthesis of serotonin and dopamine. A 2024 meta-analysis found that deficiency is associated with increased depressive symptoms, and supplementation may help restore normal neurotransmitter signaling in deficient individuals.
SAMe and methylation pathways
S-adenosylmethionine (SAMe) is a naturally occurring molecule that serves as a methyl donor in numerous biochemical reactions, including the synthesis of neurotransmitters such as serotonin, dopamine, and norepinephrine. A 2024 meta-analysis confirmed SAMe's role in supporting methylation-dependent neurotransmitter production.
Methylfolate and neurotransmitter production
L-methylfolate is the only form of folate that crosses the blood-brain barrier. It is a critical cofactor in the synthesis of serotonin, dopamine, and norepinephrine. People with MTHFR gene variants have reduced ability to convert folic acid into its active form, potentially impairing neurotransmitter production. Randomized controlled trials have shown that supplementation with L-methylfolate at 15 mg/day can improve outcomes in SSRI-resistant depression.
How These Supplements Affect Mood and Brain Function
Omega-3s reduce neuroinflammation
EPA reduces levels of pro-inflammatory cytokines in the brain, including IL-1beta, IL-6, and TNF-alpha. Chronic neuroinflammation is increasingly recognized as a contributor to depressive symptoms. A 2019 meta-analysis in Translational Psychiatry found that EPA-enriched formulations (at least 60% EPA of total EPA+DHA) significantly reduced depression severity, which may explain why EPA-rich formulations outperform DHA-only supplements in depression trials.
Vitamin D modulates the HPA axis
Vitamin D receptors are present in the hypothalamus and other brain regions that regulate the hypothalamic-pituitary-adrenal (HPA) axis. Vitamin D may help modulate cortisol and stress responses, which are frequently dysregulated in depression. However, the evidence for direct HPA axis modulation by vitamin D supplementation in depressed individuals remains preliminary.
SAMe increases neurotransmitter availability
SAMe donates methyl groups required for the enzymatic conversion of precursors into serotonin, dopamine, and norepinephrine. It also contributes to the synthesis of phosphatidylcholine, a component of neuronal cell membranes. A review of the evidence found that SAMe may increase monoamine turnover and enhance neurotransmitter receptor sensitivity.
Methylfolate supports monoamine synthesis
L-methylfolate is an essential cofactor for the enzyme that converts tryptophan into serotonin and tyrosine into dopamine and norepinephrine. When folate metabolism is impaired, as in people with MTHFR C677T variants, monoamine synthesis may be reduced. Papakostas et al. (2012) demonstrated that adjunctive L-methylfolate at 15 mg/day significantly improved depression outcomes in SSRI-resistant patients.
What Clinical Research Shows About Efficacy
Omega-3 fatty acids
A 2019 meta-analysis of 26 RCTs found that omega-3 supplementation significantly reduced depressive symptoms compared to placebo (SMD = -0.28). EPA doses of 1 to 2 grams per day appear most effective, particularly when EPA comprises at least 60% of total EPA+DHA and when used as adjunctive therapy alongside antidepressants. DHA-only formulations show weaker effects. The benefit is most pronounced in people with higher baseline inflammation.
Vitamin D
A 2024 dose-response meta-analysis of 31 RCTs with 24,189 participants found that vitamin D3 supplementation modestly reduced depressive symptoms (SMD: -0.32), with stronger effects in individuals with existing depressive symptoms (SMD: -0.57). The benefit was observed with doses of 2,000 IU daily and above. Trials lasting 8 to 24 weeks showed the strongest effects, while trials shorter than eight weeks showed minimal benefit. The evidence is strongest for people with vitamin D deficiency (below 20 ng/mL).
SAMe
A 2024 meta-analysis of 23 trials with 2,183 participants found that SAMe was superior to placebo (SMD: -0.58) and comparable to tricyclic antidepressants for treating depression. Doses of 800 to 1,600 mg per day (divided into two doses) are most commonly studied. An RCT testing 800 mg/day found a clinically relevant effect size (d = 0.72) favoring SAMe over placebo as monotherapy, though the result did not reach statistical significance in the small sample. SAMe has also shown benefit as an adjunct to SSRIs in nonresponders, though evidence for adjunctive use is mixed across studies. Some studies suggest onset of effect within 1 to 2 weeks, but this has not been rigorously confirmed in head-to-head comparisons with standard antidepressants.
Methylfolate
Two randomized, double-blind trials by Papakostas et al. found that adjunctive L-methylfolate at 15 mg/day significantly improved depression outcomes in SSRI-resistant patients, while the 7.5 mg/day dose did not show significant benefit. The effect is most pronounced when combined with SSRIs or SNRIs. Biomarkers such as elevated hs-CRP (above 3 mg/L) and high BMI may be stronger predictors of L-methylfolate response than MTHFR genotype alone. L-methylfolate alone has not been extensively studied as monotherapy for depression.
Dosing, Timing, and Formulation
Omega-3 fatty acids
Look for supplements with at least 1,000 mg of EPA per serving. The EPA-to-DHA ratio matters: meta-analyses suggest formulations where EPA comprises at least 60% of total EPA+DHA show better results in depression trials than balanced or DHA-dominant products. Triglyceride forms may absorb better than ethyl ester forms, particularly when not taken with a high-fat meal. Take with a fat-containing meal to improve absorption. Effects typically appear after 4 to 8 weeks of consistent use.
Vitamin D
Doses of 2,000 to 4,000 IU daily are standard for correcting deficiency. Vitamin D3 (cholecalciferol) is more effective than D2 (ergocalciferol) at raising blood levels. Take with a meal containing fat, as vitamin D is fat-soluble. Testing baseline levels before supplementing is essential, since excess vitamin D can cause toxicity. Retest after 8 to 12 weeks to assess response.
SAMe
Start with 400 mg twice daily and increase to 800 mg twice daily if tolerated. SAMe is best absorbed on an empty stomach, 30 minutes before meals. Enteric-coated formulations reduce gastrointestinal side effects. SAMe degrades quickly, so store it in a cool, dry place and check expiration dates. Some studies suggest effects may appear within 1 to 2 weeks, though this has not been conclusively established in rigorous head-to-head comparisons with conventional antidepressants. Important: SAMe should not be used by individuals with bipolar disorder, as clinical studies have reported a significant risk of triggering mania or hypomania.
Methylfolate
The most effective dose in clinical trials is 15 mg daily; the 7.5 mg dose did not show significant benefit over placebo. L-methylfolate is typically used as an adjunct to antidepressants. Methylfolate is water-soluble and can be taken with or without food. It's often combined with vitamin B12 and B6, which support methylation pathways. Genetic testing for MTHFR variants can help identify who is most likely to benefit.
Who Responds and Who Doesn't
Baseline nutrient status
Supplements work best when they correct a deficiency. If your omega-3 index is already optimal or your vitamin D level is 40 ng/mL, adding more won't necessarily improve mood. Conversely, someone with a vitamin D level of 15 ng/mL may see significant improvement with supplementation. Testing baseline levels before starting is the most reliable way to predict response.
Genetic factors
MTHFR gene variants reduce the body's ability to convert folic acid into methylfolate, making supplementation with the active form more effective. Similarly, genetic differences in omega-3 metabolism and vitamin D receptor function influence how well you respond to these supplements. Pharmacogenomic testing can identify these variants.
Inflammation levels
People with elevated inflammatory markers like hs-CRP or IL-6 tend to respond better to omega-3 supplementation than those with low inflammation. Research suggests that depression with high inflammation may represent a distinct subtype that's more responsive to anti-inflammatory interventions.
Medication interactions
SAMe can interact with antidepressants, particularly MAO inhibitors and SSRIs, potentially increasing serotonin to unsafe levels (serotonin syndrome). A case report documented mania with psychotic features in a patient taking SAMe concurrently with an SSRI. SAMe should also be avoided in individuals with bipolar disorder due to the risk of triggering manic episodes. Omega-3s were historically thought to have blood-thinning effects, but a systematic review found no significant impact on bleeding risk at typical supplemental doses (up to 4 g/day), even when combined with anticoagulants. Nonetheless, patients on anticoagulant therapy should inform their prescriber before starting omega-3 supplementation. Vitamin D can interact with certain medications that affect calcium metabolism. Always disclose supplement use to your prescriber.
Severity of depression
Supplements show the most consistent benefit in mild to moderate depression. Severe depression typically requires more intensive intervention, and supplements are best used as adjuncts to medication or psychotherapy rather than standalone treatments.
Turning Research Into a Strategy That Works for You
Knowing your baseline biomarker levels before starting a supplement is more informative than guessing. If you're considering omega-3s, an omega-3 index test shows your current EPA and DHA levels. For vitamin D, a 25-hydroxyvitamin D test reveals whether you're deficient, sufficient, or optimal. Homocysteine and folate levels can indicate whether methylation pathways are functioning efficiently.
Tracking changes over time matters more than any single data point. Retest after 8 to 12 weeks of supplementation to see if levels have shifted and whether symptoms have improved. This approach removes guesswork and shows whether the intervention is working for your specific biology.
Relevant biomarkers to consider before supplementing for depression include:
- Omega-3 Index (EPA + DHA as a percentage of total red blood cell fatty acids)
- 25-Hydroxyvitamin D (sufficiency generally defined as above 30 ng/mL; the 2024 Endocrine Society guidelines note that an optimal target for disease prevention has not been established in clinical trials)
- Homocysteine (elevated levels suggest impaired methylation)
- Folate and B12 (low levels can impair neurotransmitter synthesis)
- hs-CRP (elevated inflammation may predict omega-3 response)
What Your Lab Results Can Tell You About Your Supplement Strategy
If you're taking supplements to support mood, Superpower's 100+ biomarker panel includes the markers that show whether your approach is working. Omega-3 levels, vitamin D status, homocysteine, folate, and inflammatory markers like hs-CRP reveal whether your current regimen is addressing the underlying biochemical imbalances that contribute to depression. You're not guessing based on how you feel; you're adjusting based on what your body is actually doing.
.avif)